JCMAX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JCMAX Analyst Rating

Moderate Buy

180 Buy

17 Hold

3 Sell

Based on the consensus analyst ratings on 200 stocks held in JCMAX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JCMAX Analyst Price Target

Average Price Target

$65.41

Based on 200 Wall Street analysts offering 12 month price targets to JPMorgan Mid Cap Equity Fund Cl A holdings in the last 3 months. The average price target is $65.41 with a high forecast of $76.42 and a low forecast of $54.76. The average price target represents a 11.02% change from the last price of $58.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"$53","59":"$59","65":"$65","71":"$71","77":"$77"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76.419,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.411,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.758,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,59,65,71,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.76,60.11838461538461,61.47676923076923,62.835153846153844,64.19353846153845,65.55192307692307,66.9103076923077,68.2686923076923,69.62707692307691,70.98546153846154,72.34384615384616,73.70223076923077,75.06061538461537,{"y":76.419,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.76,59.27161538461538,59.78323076923077,60.29484615384615,60.80646153846154,61.31807692307692,61.829692307692305,62.341307692307694,62.85292307692308,63.36453846153846,63.87615384615385,64.38776923076924,64.89938461538462,{"y":65.411,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.76,58.45215384615384,58.14430769230769,57.836461538461535,57.528615384615385,57.22076923076923,56.91292307692308,56.60507692307692,56.29723076923077,55.989384615384616,55.681538461538466,55.37369230769231,55.06584615384615,{"y":54.758,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.31,"date":1714521600000,"info":"<div>Price: <b>$56<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":57.08,"date":1717372800000,"info":"<div>Price: <b>$57<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":56.5,"date":1719792000000,"info":"<div>Price: <b>$57<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.19,"date":1722470400000,"info":"<div>Price: <b>$58<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":59.36,"date":1725321600000,"info":"<div>Price: <b>$59<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":60.91,"date":1727740800000,"info":"<div>Price: <b>$61<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":61.24,"date":1730419200000,"info":"<div>Price: <b>$61<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.18,"date":1733097600000,"info":"<div>Price: <b>$66<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":61.9,"date":1735776000000,"info":"<div>Price: <b>$62<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":64.09,"date":1738540800000,"info":"<div>Price: <b>$64<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":61.5,"date":1740960000000,"info":"<div>Price: <b>$62<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":59.4,"date":1743465600000,"info":"<div>Price: <b>$59<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.76,"date":1746057600000,"info":"<div>Price: <b>$59<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$76.42

Average Price Target$65.41

Lowest Price Target$54.76

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

JCMAX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

PCVX

Vaxcyte, Inc.

11 Buy

0 Hold

0 Sell

Strong Buy

$117.88

xxxxxxxxxxxxxxxxxxxxxxxxxxx

VKTX

Viking Therapeutics

15 Buy

2 Hold

0 Sell

Strong Buy

$88.47

xxxxxxxxxxxxxxxxxxxxxxxxxxx

JAZZ

Jazz Pharmaceuticals

17 Buy

1 Hold

0 Sell

Strong Buy

$188.29

xxxxxxxxxxxxxxxxxxxxxxxxxxx

RVMD

Revolution Medicines, Inc.

12 Buy

0 Hold

0 Sell

Strong Buy

$70.18

xxxxxxxxxxxxxxxxxxxxxxxxxxx

MRVL

Marvell Technology Group

26 Buy

3 Hold

0 Sell

Strong Buy

$99.42

JCMAX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

PLTR

Palantir Technologies Inc.

3 Buy

11 Hold

4 Sell

Hold

$100.13

xxxxxxxxxxxxxxxxxxxxxxxxxxx

CRI

Carter's Inc

0 Buy

2 Hold

3 Sell

Moderate Sell

$31.40

xxxxxxxxxxxxxxxxxxxxxxxxxxx

DFS

Discover Financial Services

5 Buy

5 Hold

0 Sell

Moderate Buy

$190.38

xxxxxxxxxxxxxxxxxxxxxxxxxxx

Trane Technologies Plc

4 Buy

7 Hold

1 Sell

Hold

$399.90

xxxxxxxxxxxxxxxxxxxxxxxxxxx

WRB

W. R. Berkley Corporation

3 Buy

7 Hold

1 Sell

Hold

$68.30

JCMAX Mutual Fund FAQ

What is JCMAX’s average 12-month price target, according to analysts?

Based on analyst ratings, JPMorgan Mid Cap Equity Fund Cl A’s 12-month average price target is 65.41.

What is JCMAX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for JCMAX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JCMAX a Buy, Sell or Hold?

JPMorgan Mid Cap Equity Fund Cl A has a consensus rating of Moderate Buy which is based on 180 buy ratings, 17 hold ratings and 3 sell ratings.

What is JPMorgan Mid Cap Equity Fund Cl A’s price target?

The average price target for JPMorgan Mid Cap Equity Fund Cl A is 65.41. This is based on 200 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $76.42 ,the lowest forecast is $54.76. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about JPMorgan Mid Cap Equity Fund Cl A?

JPMorgan Mid Cap Equity Fund Cl A’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 200 Wall Streets Analysts.

How can I buy shares of JCMAX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing